KIMS Q4 FY26 Results: Revenue Up 34.8%, PAT Drops

Stock snapshot and why the results matter

Krishna Institute of Medical Sciences Ltd (KIMS) reported its Q4 FY26 and FY26 numbers with a clear split between strong top-line growth and weaker bottom-line performance. The stock level cited alongside the update was 814.00, with a move of -1.20. The company’s quarterly disclosures highlight a rise in revenue and operating metrics such as ARPOB and ARPP, even as EBITDA margins and profit after tax fell versus prior periods.

For investors tracking hospital operators, this combination matters because revenue growth in healthcare is often assessed alongside operating leverage and margin stability. In KIMS’s case, the latest quarter includes robust year-on-year expansion, but the profitability picture looks softer when compared with FY25.

Q4 FY26 consolidated highlights: revenue crosses Rs 1,000 crore

KIMS disclosed Q4 FY26 consolidated revenue from operations of Rs 1,075 crore. This was reported as a 34.8% year-on-year increase and 7.7% quarter-on-quarter growth. Consolidated EBITDA (Pre-INDAS) came in at Rs 197 crore, with no growth year-on-year and a 1.8% increase quarter-on-quarter.

The company also provided an additional view excluding other income. Consolidated EBITDA (Pre-INDAS and excluding Other Income) was Rs 187 crore, a 2.7% year-on-year decline and 0.6% quarter-on-quarter decline. This split is important because other income can change quarter to quarter and affect headline operating profitability.

Q4 FY26 standalone highlights: margins and PAT weakened

On a standalone basis for Q4 FY26, KIMS reported total revenue of Rs 1,084 crore. This was a 35.3% year-on-year increase and 8.1% quarter-on-quarter increase. Standalone EBITDA was Rs 216 crore, growing 6.8% year-on-year and 5.9% quarter-on-quarter.

However, EBITDA margin was reported at 19.9% versus 25.3% in Q4 FY25 and 20.4% in Q3 FY26. Standalone PAT was reported at Rs 33 crore in Q4 FY26, compared with Rs 106 crore in Q4 FY25 and Rs 52 crore in Q3 FY26. KIMS also reported cash and cash equivalents of Rs 90 crore as on 31 March 2026.

FY26 standalone performance: revenue grew, profit fell

For FY26 on a standalone basis, KIMS reported total revenue of Rs 3,931 crore, reflecting 28.2% year-on-year growth. EBITDA for the year was Rs 828 crore, up 1.6% year-on-year. But the margin compressed to 21.1% versus 26.6% in FY25.

PAT for FY26 was Rs 242 crore versus Rs 415 crore in FY25. The company also reported consolidated EPS for FY26 at Rs 6.03, a 37.2% year-on-year decline. In contrast, FY25 financial highlights cited total revenue of Rs 3,067 crore, EBITDA of Rs 815 crore, and net income of Rs 415 crore.

Operating metrics update: ARPOB, ARPP and volumes

KIMS reported ARPOB growth of 13.7% year-on-year and 1.7% quarter-on-quarter in Q4 FY26. ARPP rose 14% year-on-year and 3.5% quarter-on-quarter for the same quarter. For FY26, ARPOB grew 14% year-on-year and ARPP grew 11.4% year-on-year.

The FY26 update also included volume growth, with IP and OP volume up 15.4% and 25.4% year-on-year, respectively. Another operational snapshot in the data set cited inpatient volume of 61,139 (up 13.2% year-on-year, down 4.9% quarter-on-quarter) and outpatient volume of 585,499 (up 24.5% year-on-year, down 1.2% quarter-on-quarter). The same snapshot noted 24 hospitals across 5 states and the launch of 7 new hospitals in 2025, with a release date listed as February 09, 2026.

Quarterly financial trend table (figures in Rs crore)

The provided quarterly table shows a steady rise in net sales between Mar 2025 and Mar 2026, while profit after tax and EPS moved within a narrower band.

Earnings snapshot: revenue 456 crore and net profit 65 crore

Alongside the detailed Q4 FY26 and FY26 highlights, the data also included an earnings snapshot for the last earnings date, listed as Q4 FY25-26 on 15 May 2026. This snapshot listed revenue of 456 (treated as Rs 456 crore) with QoQ growth of 3.24% and YoY growth of 31.89%. It listed gross profit of 105 (Rs 105 crore) with QoQ change of -0.10% and YoY change of 12.18%.

The same snapshot listed net profit of 65 (Rs 65 crore) with QoQ change of -9.10% and YoY change of -29.52%. Separately, one line stated that KIMS’s net profit fell -58.25% since the same period last year to Rs 42.50 crore in Q4 2025-2026, and that net profits fell -20.41% on a quarterly basis. These figures indicate that profit comparisons vary across presented summaries and periods, but the common thread is that profit growth lagged revenue growth.

Market impact: what investors can verify from the numbers

The most direct, measurable takeaway is that revenue grew sharply in Q4 FY26, with consolidated revenue from operations reported at Rs 1,075 crore and standalone revenue at Rs 1,084 crore. At the same time, margin pressure shows up in the standalone EBITDA margin of 19.9% versus 25.3% in Q4 FY25, and in the full-year FY26 margin of 21.1% versus 26.6% in FY25.

Profitability also weakened on the full-year view, with FY26 PAT at Rs 242 crore versus Rs 415 crore in FY25, and FY26 consolidated EPS at Rs 6.03, down 37.2% year-on-year. For hospital operators, these deltas can influence valuation debates around expansion pace, fixed-cost absorption, and the sustainability of higher ARPOB and ARPP.

Corporate actions and key dates mentioned

The information set included a “Newspaper Publication - Intimation about EGM,” without additional details. It also cited the 22nd Annual General Meeting scheduled for Thursday, 29 August 2024 at 4:00 PM, along with references to revised notices and post-AGM proceedings and results.

On the results calendar, the “last earnings date” was stated as 15 May 2026 for Q4 FY25-26, and the “upcoming earnings date” was also stated as 15 May 2026 in the same material. Readers should treat the date references as provided in the source text.

Conclusion

KIMS reported strong Q4 FY26 revenue growth and improving patient and bed-level realisations, but the quarter and year were marked by weaker margins and lower profits versus FY25. The next cues for investors, based on the provided disclosures, will come from formal company communications around shareholder meetings and subsequent earnings updates.